Literature DB >> 3415476

Specific neuro-radiological diagnosis of herpes encephalitis in an animal model.

G M Cleator1, P E Klapper, A G Lewis, H L Sharma, M Longson.   

Abstract

The potential of utilizing a radio-labelled derivative of the antiviral drug (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVDU) for the specific, non-invasive, in vivo diagnosis of Herpes simplex virus encephalitis (HSVE) was investigated in a rat model of the disease. Following pharmacological disruption of the blood brain barrier radiolabelled IVDU was administered by intra-carotid injection. Brain radioactivity was compared between control and infected animals via gamma camera scintigraphy. After clearance of non-metabolized drug, markedly higher levels of activity were found in infected brain. Post-mortem studies of cryostat sections of brain examined by autoradiography and immunochemical staining showed the radioactivity selectively accumulated in areas of virus infection. These results indicate that radio-labelled derivatives of antiviral drugs may allow the specific neuro-radiological diagnosis of HSVE.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3415476     DOI: 10.1007/BF01314647

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  19 in total

1.  Mild forms of herpes encephalitis.

Authors:  P E Klapper; G M Cleator; M Longson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-11       Impact factor: 10.154

2.  Prospects for the use of radiolabeled antiviral drugs in the diagnosis of herpes simplex encephalitis.

Authors:  R W Price; Y Saito; J J Fox
Journal:  Biochem Pharmacol       Date:  1983-09-01       Impact factor: 5.858

3.  Quantitative autoradiographic mapping of herpes simplex virus encephalitis with a radiolabeled antiviral drug.

Authors:  Y Saito; R W Price; D A Rottenberg; J J Fox; T L Su; K A Watanabe; F S Philips
Journal:  Science       Date:  1982-09-17       Impact factor: 47.728

4.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

5.  Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.

Authors:  B Sköldenberg; M Forsgren; K Alestig; T Bergström; L Burman; E Dahlqvist; A Forkman; A Frydén; K Lövgren; K Norlin
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

6.  Synthesis of 131I, 125I and 82Br labelled (E)-5-(2-halovinyl)-2'-deoxyuridines.

Authors:  J Samuel; E E Knaus; L I Wiebe; D L Tyrrell
Journal:  Int J Appl Radiat Isot       Date:  1984-11

7.  Pharmacokinetics and metabolism of E-5-(2-[131I]iodovinyl)-2'-deoxyuridine in dogs.

Authors:  J Samuel; M J Gill; T Iwashina; D R Tovell; D L Tyrrell; E E Knaus; L I Wiebe
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

8.  Etoposide-induced blood-brain barrier disruption. Effect of drug compared with that of solvents.

Authors:  M K Spigelman; R A Zappulla; J Johnson; S J Goldsmith; L I Malis; J F Holland
Journal:  J Neurosurg       Date:  1984-10       Impact factor: 5.115

9.  Specific phosphorylation of E-5-(2-iodovinyl)-2'-deoxyuridine by herpes simplex virus-infected cells.

Authors:  J Descamps; E De Clercq
Journal:  J Biol Chem       Date:  1981-06-25       Impact factor: 5.157

10.  Ocular penetration of (125I)IVDU, a radiolabeled analogue of bromovinyldeoxyuridine.

Authors:  P C Maudgal; A M Verbruggen; E De Clercq; R Busson; R Bernaerts; M de Roo; C Ameye; L Missotten
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-01       Impact factor: 4.799

View more
  2 in total

1.  HM-PAO-imaging and herpes encephalitis.

Authors:  G M Cleator; A G Lewis; P E Klapper; H L Sharma; A M Smith
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 2.  Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes.

Authors:  Mike Bray; Michele Di Mascio; Fabian de Kok-Mercado; Daniel J Mollura; Elaine Jagoda
Journal:  Antiviral Res       Date:  2010-08-13       Impact factor: 5.970

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.